Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.383
+0.002 (0.45%)
At close: Apr 28, 2026, 4:00 PM EDT
0.380
-0.003 (-0.76%)
After-hours: Apr 28, 2026, 7:26 PM EDT
Scienture Holdings Employees
As of December 31, 2025, Scienture Holdings had 9 total employees, including 4 full-time and 5 part-time employees. The number of employees decreased by 10 or -52.63% compared to the previous year.
Employees
9
Change (1Y)
-10
Growth (1Y)
-52.63%
Revenue / Employee
$47,957
Profits / Employee
-$4,612,474
Market Cap
15.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9 | -10 | -52.63% |
| Dec 31, 2024 | 19 | 0 | - |
| Dec 31, 2023 | 19 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 390,000 |
| Johnson & Johnson | 138,200 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
| Jin Medical International | 273 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 17 |
| Genenta Science | 9 |
SCNX News
- 4 weeks ago - SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - GlobeNewsWire
- 3 months ago - SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 3 months ago - SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - GlobeNewsWire
- 4 months ago - SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - GlobeNewsWire
- 4 months ago - SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 5 months ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 5 months ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire